Residency · Residency · Gastroenterology

Colorectal Cancer Screening and Polyp Management

Epidemiology

Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the United States, with a lifetime risk of approximately 4 to 5% in average-risk individuals. The incidence has been declining in the population over 50, reflecting the impact of screening programs, but is rising in adults under 50 years of age. Early-onset colorectal cancer now accounts for 10 to 12% of all cases. Modifiable risk factors include obesity, red and processed meat consumption, smoking, alcohol use, sedentary lifestyle, and diabetes. Protective factors include physical activity, aspirin use (the USPSTF cardiovascular prevention recommendation may confer co-benefit for CRC), fiber, and calcium and vitamin D (based on observational data).

Screening Guidelines — Average Risk

ACS (2018) / USPSTF (2021) / ACG (2021)

Current guidelines from the American Cancer Society, United States Preventive Services Task Force, and American College of Gastroenterology uniformly recommend initiating colorectal cancer screening at age 45, lowered from the previous threshold of 50 years. Screening should continue through age 75, with individualized decisions for those aged 76 to 85 based on health status, life expectancy, and prior screening history, and is not recommended beyond age 85. The ACG designates colonoscopy every 10 years as the preferred screening method, while the USPSTF and ACS offer a choice among multiple options.

Screening Modalities

Colonoscopy remains the gold standard for colorectal cancer screening, performed every 10 years. It is both diagnostic and therapeutic, allowing detection and removal of precancerous lesions in a single session, with a sensitivity exceeding 95% for colorectal cancer and 75 to 95% for advanced adenomas. It requires bowel preparation and sedation, and carries a perforation risk of approximately 1 in 1,000 to 1 in 3,000 procedures.

The fecal immunochemical test (FIT) detects human hemoglobin without dietary restrictions and must be performed annually for cumulative benefit. Its sensitivity is 74% for colorectal cancer and 24% for advanced adenomas per individual round. The FIT-fecal DNA test (Cologuard), performed every 3 years, combines multi-target stool DNA testing with a sensitivity of 92% for colorectal cancer and 42% for advanced adenomas as demonstrated in the DeeP-C trial, though its specificity of 87% results in a higher false-positive rate than FIT alone. Any positive stool-based test requires follow-up colonoscopy.

CT colonography is performed every 5 years, with a sensitivity of 90% for polyps 10 mm or larger. It requires bowel preparation, involves radiation exposure, and identifies extracolonic findings in 5 to 37% of cases. Flexible sigmoidoscopy, performed every 5 to 10 years (or every 10 years combined with annual FIT), has declining availability in the United States. Capsule colonoscopy is FDA-approved for CRC screening in patients unable or unwilling to undergo standard colonoscopy but has limited availability.

High-Risk Screening

Patients with a first-degree relative diagnosed with colorectal cancer or advanced adenoma before age 60, or two or more first-degree relatives at any age, should begin colonoscopy at age 40 or 10 years before the youngest affected relative, whichever is earlier, with repeat screening every 5 years. For those with a first-degree relative diagnosed at age 60 or later, colonoscopy should begin at age 40 and repeat every 10 years, following the average-risk schedule. Patients with inflammatory bowel disease should begin surveillance 8 years after symptom onset. Screening for hereditary syndromes is covered in the Hereditary CRC Syndromes lecture.

Polyp Types and Classification

Conventional Adenomas

Tubular adenomas account for 80% of adenomas and contain less than 25% villous component, carrying the lowest malignant potential. Tubulovillous adenomas have 25 to 75% villous component and intermediate risk. Villous adenomas contain more than 75% villous component and carry the highest malignant potential, with 15 to 25% harboring carcinoma. An advanced adenoma is defined by any of the following: size of 10 mm or greater, villous histology, or high-grade dysplasia.

Serrated Lesions

Hyperplastic polyps are the most common serrated lesion, typically measuring less than 5 mm and located in the rectosigmoid. They carry low malignancy risk and do not require accelerated surveillance unless they are 10 mm or larger or right-sided. Sessile serrated lesions (SSLs, formerly sessile serrated adenoma/polyps) are right-sided, flat or sessile lesions often covered by a mucus cap. Histologically, they demonstrate boot-shaped crypts with basal dilation and horizontal growth. They harbor the BRAF V600E mutation and serve as precursors to microsatellite instability-high colorectal cancer through the serrated neoplasia pathway, which accounts for 15 to 30% of all CRC. SSLs with cytologic dysplasia carry higher risk and are managed as high-risk lesions. Traditional serrated adenomas (TSAs) are rare (approximately 1%), harbor KRAS or BRAF mutations, tend to be left-sided, and demonstrate villiform architecture with eosinophilic cytoplasm and ectopic crypt formation.

Paris Classification (Endoscopic Morphology)

The Paris classification categorizes polyp morphology as 0-Ip (pedunculated), 0-Is (sessile), 0-IIa (slightly elevated or flat elevated), 0-IIb (completely flat), 0-IIc (slightly depressed), and 0-III (excavated or ulcerated). Depressed (IIc) and mixed types carry the highest malignancy risk relative to their size.

<image>A comprehensive visual reference chart of colorectal polyp types with endoscopic, histologic, and molecular features. Create a 2x3 grid. Panel 1 "Tubular Adenoma": endoscopic image showing a smooth, rounded, pink-red pedunculated polyp on a stalk; histologic inset showing tubular glands with nuclear stratification and elongation. Panel 2 "Villous Adenoma": endoscopic image showing a large, cauliflower-like sessile lesion with frond-like projections; histologic inset showing finger-like villous projections. Panel 3 "Sessile Serrated Lesion": endoscopic image showing a flat, pale lesion with a mucus cap in the right colon, barely visible on white light (include NBI view showing irregular surface pattern); histologic inset showing dilated, boot-shaped crypts with basal serration and horizontal growth along the muscularis mucosae. Panel 4 "Hyperplastic Polyp": endoscopic image showing a small (<5 mm), pale, sessile lesion in the rectosigmoid; histologic inset showing serrated epithelium limited to the upper half of the crypt. Panel 5 "Traditional Serrated Adenoma": endoscopic image showing a protuberant, villiform lesion; histologic inset showing eosinophilic cytoplasm and ectopic crypt formation. Panel 6 "Malignant Polyp (T1)": endoscopic image showing a large sessile polyp with surface ulceration and irregular pattern on NBI. Include molecular pathway annotations: APC-WNT pathway (conventional adenomas), BRAF-CpG island methylation (serrated pathway). Label the serrated neoplasia pathway: SSL -> SSL with dysplasia -> MSI-high CRC.</image>

Endoscopic Polyp Removal Techniques

Cold Snare Polypectomy

Cold snare polypectomy is the standard technique for polyps measuring 4 to 9 mm, and up to 10 to 20 mm in expert hands. The absence of electrocautery reduces the risk of delayed bleeding, perforation, and post-polypectomy syndrome. The CARE (Complete Adenoma REsection) study highlighted that incomplete resection rates can reach 10% with cold snare for 5 to 20 mm polyps, emphasizing the importance of ensuring adequate margins.

Hot Snare Polypectomy

Hot snare polypectomy uses electrocautery and is indicated for pedunculated polyps and larger sessile polyps exceeding 10 mm. While electrocautery assists with hemostasis, it increases the risk of perforation and delayed bleeding. For pedunculated polyps with thick stalks or heads exceeding 10 mm, prophylactic clip or endoloop placement should be considered.

Endoscopic Mucosal Resection (EMR)

EMR is the standard approach for sessile polyps 20 mm or larger, including laterally spreading tumors. The technique involves submucosal injection with saline mixed with methylene blue or indigo carmine, with or without epinephrine, to lift the lesion from the muscularis propria. Piecemeal resection is acceptable for benign lesions, though en bloc resection is preferred when technically feasible for polyps exceeding 20 mm. Incomplete resection and recurrence rates of 15 to 30% for piecemeal EMR mandate a specific surveillance schedule: follow-up at 6 months to check for residual or recurrent tissue, then at 12 months, then at 3 years.

Endoscopic Submucosal Dissection (ESD)

ESD enables en bloc resection of large lesions exceeding 20 mm regardless of size, with a higher complete resection rate than piecemeal EMR (92 to 97% versus 70 to 85%). The tradeoffs include longer procedure times, a higher perforation rate (3 to 10%), and the requirement for advanced training. ESD is preferred for lesions with suspected superficial submucosal invasion, non-granular laterally spreading tumors, lesions with depression (Paris IIc), and recurrent lesions after prior EMR.

Non-Lifting Sign

The non-lifting sign, in which submucosal injection fails to lift the lesion, suggests deep submucosal invasion or prior scarring. In a lesion that has not been previously manipulated, surgical referral should be considered. In the setting of a prior biopsy or tattoo site, the fibrosis may be benign, and careful EMR or ESD may be attempted.

Surveillance After Polypectomy (USMSTF 2020)

Normal Colonoscopy (No Polyps)

Patients with a normal colonoscopy should have repeat colonoscopy in 10 years.

Low-Risk Findings

Patients with 1 to 2 tubular adenomas smaller than 10 mm should return in 7 to 10 years. Small hyperplastic polyps (less than 10 mm) in the rectosigmoid warrant repeat colonoscopy at 10 years. One to 2 sessile serrated lesions smaller than 10 mm without dysplasia warrant colonoscopy in 5 to 10 years.

High-Risk Findings

Patients with 3 to 4 tubular adenomas smaller than 10 mm should return in 3 to 5 years. Any of the following findings warrant colonoscopy at 3 years: 5 to 10 adenomas, an adenoma of 10 mm or larger, villous histology, high-grade dysplasia, a sessile serrated lesion of 10 mm or larger, an SSL with dysplasia, or a traditional serrated adenoma.

Very High-Risk Findings

Patients with more than 10 adenomas should return in 1 year and be referred for genetic evaluation. Piecemeal resection of a polyp 20 mm or larger requires a first follow-up at 6 months to check for residual or recurrent tissue, followed by 12 months and then 3 years.

Malignant Polyp (T1 Carcinoma in a Polyp)

Favorable criteria for endoscopic cure include complete resection with clear margins of at least 1 mm, well or moderately differentiated histology, no lymphovascular invasion, and no tumor budding. Pedunculated polyps with favorable features (Haggitt level 1 to 3) are managed with surveillance at 3 to 6 months, then 1 year, then 3 years. Sessile polyps with favorable features (sm1 invasion only with clear deep margin) may be managed with surveillance, though surgical referral for discussion is reasonable. Any unfavorable features (incomplete resection, poor differentiation, lymphovascular invasion, or tumor budding) warrant surgical resection with segmental colectomy and lymph node dissection.

<image>A post-polypectomy surveillance algorithm displayed as a tiered diagram. Three tiers from bottom to top representing increasing risk. Bottom tier "Low Risk" (green): Normal colonoscopy -> 10 years; 1-2 small (<10 mm) tubular adenomas -> 7-10 years; 1-2 small SSLs without dysplasia -> 5-10 years. Middle tier "High Risk" (yellow): 3-4 adenomas -> 3-5 years; adenoma >=10 mm, villous histology, or HGD -> 3 years; SSL >=10 mm or with dysplasia -> 3 years; 5-10 adenomas -> 3 years. Top tier "Very High Risk" (red): >10 adenomas -> 1 year + genetic evaluation; piecemeal EMR of >=20 mm -> 6 months first check, then 12 months, then 3 years. Side box for "Malignant Polyp": favorable features (clear margins, well-differentiated, no LVI) -> surveillance; unfavorable features -> surgical resection. Include the key definitions: advanced adenoma = >=10 mm, villous, or HGD. Note: "Based on USMSTF 2020 recommendations."</image>

Quality Metrics in Colonoscopy

Adenoma Detection Rate (ADR)

The adenoma detection rate is the percentage of screening colonoscopies in which at least one adenoma is detected. The minimum acceptable threshold is 25% overall (30% in men and 20% in women). Each 1% increase in ADR is associated with a 3% decrease in interval colorectal cancer risk, as demonstrated in the landmark Corley study. ADR is the single most important quality indicator in colonoscopy.

Other Quality Metrics

Additional quality metrics include a cecal intubation rate of 95% or higher with photodocumentation of cecal landmarks, a withdrawal time of at least 6 minutes in negative screening colonoscopies, adequate bowel preparation (Boston Bowel Preparation Scale of 6 or higher with each segment scoring at least 2) in 85% or more of examinations, a serrated lesion detection rate of at least 5% (an emerging metric), and a polyp detection rate of at least 40%.

AI-Assisted Polyp Detection

Computer-aided detection (CADe) systems use artificial intelligence and deep learning algorithms to provide real-time polyp detection during colonoscopy. Multiple randomized controlled trials have demonstrated an increase in ADR of 9 to 15%, primarily through improved detection of small adenomas and serrated lesions. FDA-cleared devices include GI Genius (Medtronic), ENDO-AID (Olympus), and CAD EYE (Fujifilm). These systems serve as quality improvement tools for all endoscopists and may reduce operator-dependent variability.

Early-Onset Colorectal Cancer

Early-onset colorectal cancer, diagnosed before age 50 (or before 45 by some definitions), is a growing concern with a rising incidence of approximately 2% per year in the 20 to 29 age group and 1.5% per year in the 30 to 39 age group. These tumors are more commonly left-sided, involving the rectum and distal colon, and are more likely to present at advanced stages due to diagnostic delay and lower screening rates. Twenty to 25% of patients with early-onset CRC have identifiable germline mutations, compared to 5 to 10% in older CRC, making genetic testing recommended for all cases. Risk factors under active investigation include obesity, ultra-processed foods, microbiome changes, antibiotic exposure, and sedentary lifestyle.

Key Clinical Pearls

• Screening should begin at age 45 for average-risk individuals (ACS 2018, USPSTF 2021, ACG 2021)
• ADR is the single most important quality metric in colonoscopy — each 1% increase reduces interval CRC risk by 3%
• Sessile serrated lesions are frequently missed (flat, mucus-capped, right-sided) and are precursors to 15-30% of CRC via the serrated pathway
• Cold snare polypectomy is standard for polyps 4-9 mm — no electrocautery needed; reduces complications
• Piecemeal EMR of large polyps requires follow-up at 6 months, then 12 months, then 3 years — recurrence rate 15-30%
• Malignant polyp with favorable features (clear margins, no LVI, well-differentiated) may be managed with surveillance alone — avoids surgery
• Early-onset CRC (<50 years) is increasing; 20-25% have germline mutations; refer for genetic counseling
• AI-assisted polyp detection increases ADR by 9-15% and is becoming standard in endoscopy practice

References

1. Gupta S, et al. AGA Clinical Practice Guidelines on Management of Colorectal Polyps. Gastroenterology. 2020;158(4):1131-1153.
2. Shaukat A, et al. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021;116(3):458-479.
3. Gupta S, et al. USMSTF Recommendations for Follow-Up After Colonoscopy and Polypectomy: 2020 Update. Gastroenterology. 2020;158(4):1131-1153.
4. Corley DA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298-1306.
5. Siegel RL, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109(8):djw322.

Read this lecture as Markdown